Funding sources This project was funded in part by NIH CTSA Grant #UL1 RR024982 and the American College of Rheumatology/Arthritis Foundation Bridge Funding Grant (BFC).
EPIDEMIOLOGY AND HEALTH SERVICES RESEARCH
A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus
Article first published online: 13 SEP 2012
© 2012 The Authors. BJD © 2012 British Association of Dermatologists
British Journal of Dermatology
Volume 168, Issue 1, pages 145–153, January 2013
How to Cite
Vasquez, R., Wang, D., Tran, Q.P., Adams-Huet, B., Chren, M.-M., Costner, M.I., Cohen, J.B., Werth, V.P. and Chong, B.F. (2013), A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. British Journal of Dermatology, 168: 145–153. doi: 10.1111/j.1365-2133.2012.11106.x
Conflicts of interest V.P.W. is a consultant for Pfizer Incorporated, Medimmune, Genentech Incorporated, Novartis International AG, Celgene Corporation, Stiefel Laboratories, Incorporated, Rigel Pharmaceuticals, Amgen Incorporated, and Astion Pharma. V.P.W. has also received grants and honoraria from Celgene Corporation, Amgen Incorporated, and Astion Pharma. B.F.C. is an investigator for Celgene Corporation and Amgen Incorporated.
R. Vasquez and D. Wang contributed equally to this work, and are co-first authors.
- Issue published online: 21 DEC 2012
- Article first published online: 13 SEP 2012
- Accepted manuscript online: 18 JUN 2012 03:15PM EST
- Accepted for publication 11 June 2012
Background A study at the University of Pennsylvania (UPenn) Medical Center demonstrated that quality of life in patients with cutaneous lupus erythematosus (CLE) is negatively impacted. Whether patients with CLE in other geographic locations have similar quality of life is unknown.
Objectives We sought to compare quality of life indicators between patients with CLE at the University of Texas Southwestern (UTSW) Medical Center at Dallas and those at UPenn.
Methods Patients with CLE (total n = 248) at UTSW (n = 91) and UPenn (n = 157) completed the Skindex-29 + 3 and Short Form-36 (SF-36) surveys related to quality of life. Additional information, including demographics, presence of systemic lupus erythematosus (SLE) and disease severity, was collected from UTSW patients with CLE.
Results Most Skindex-29 + 3 and SF-36 subdomain scores between UTSW and UPenn patients with CLE were similar. However, UTSW patients with CLE were significantly more affected in the functioning and lupus-specific Skindex-29 + 3 domains, and physical functioning, role-physical and general health SF-36 subscales than UPenn patients with CLE (P < 0·05). Factors related to poor quality of life in UTSW patients with CLE include sex, income, education, presence of SLE, and skin disease activity.
Conclusions Most quality of life indicators were similar between the two CLE populations. Differences in psychosocial behaviour, and a larger proportion of patients with SLE and females in the UTSW group likely attributed to differences in a minority of Skindex-29 + 3 and SF-36 subdomains. Capturing data from CLE populations in different locations provides a more thorough picture of the quality of life that patients with CLE experience on a daily basis with special attention to quality of life issues in select patients with CLE.